Guardant Health's MCD test earns FDA breakthrough designation
This methylation-based blood test is designed for the screening of various types of cancer in people who are 45 or above and are at a typical average cancer risk.
The tested cancers include colorectal, oesophageal, bladder, gastric, lung, liver, pancreas, and ovarian.
The FDA's designation for the MCD test follows its selection by the National Cancer Institute (NCI) for the Vanguard Study assessing the technology.
This test was selected based on its predictive performance for cancer presence and for identifying the origin of the cancer tissue.
At the 2025 American Society for Clinical Oncology Annual Meeting in Illinois, US, Guardant Health presented data from a case-control cohort of the Shield MCD test.
The findings demonstrated the test's specificity and sensitivity, along with accuracy in determining the cancer signal of origin across various types of tumours.
It exhibits 98.6% specificity and 75% sensitivity for detecting cancers, as per the data.
The sensitivity range for individual cancers varied between 62% and 96%, with primary or secondary cancer signal origin accuracy reaching 92%.
The breakthrough device designation is awarded to a select group of medical devices that show potential in treating or diagnosing life-threatening conditions compared to existing options.
Guardant Health co-CEO and co-founder AmirAli Talasaz said: 'Every late-stage cancer we avert is a win for patients and for the entire healthcare system.
'This recognition by the FDA shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw. We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly.'
Last year, the company expanded its market reach by striking a deal to promote its range of liquid and tissue biopsy tests for cancer screening in the Middle East and North Africa region.
"Guardant Health's MCD test earns FDA breakthrough designation" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
GSK provides update on US FDA advisory committee review of Blenrep
GSK (GSK) notes that the U.S. FDA Oncologic Drugs Advisory Committee voted against the overall benefit/risk profile at the proposed dosage of Blenrep combinations. The belantamab mafodotin combinations were evaluated in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will consider the recommendation of the committee as it finalises its review on Blenrep in advance of the July 23 PDUFA date. GSK remains confident in the benefit/risk profile of Blenrep and will continue to work closely with the FDA as they complete their review for Blenrep in patients with relapsed or refractory multiple myeloma where there is high unmet need for novel treatment options that extend survival. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
3 hours ago
- Yahoo
Kraft Heinz, General Mills to remove all artificial dyes from food products
Kraft Heinz, manufacturer of beloved food and drink products from the classic Kraft Mac and Cheese and Heinz ketchup to Kool-Aid and Jell-O, will eliminate the use of all artificial dyes in its products by the end of 2027, the company announced Tuesday. In a June 17 press release, the company said "nearly" 90% of its products were already free of Food, Drug & Cosmetic (FD&C) colors, also known as artificial or synthetic food dyes, and that it would be removing them from the remaining 10% of its products. The manufacturer also said it would not launch any new products using the dyes, effective immediately. The FD&C dyes in question have been and still are allowed for use in food and drink products under U.S. Food and Drug Administration (FDA) guidelines. However, an announcement from Health Secretary Robert F. Kennedy Jr in April indicated the agency is looking to revoke the approval of at least eight "petroleum-based synthetic dyes" in favor of "natural alternatives." Before the end of 2027, Kraft Heinz intends to replace the dyes with natural alternatives or "reinvent" new colors and shades for products where natural replacement color matches are not available. "As a food company with a 150+ year heritage, we are continuously evolving our recipes, products, and portfolio to deliver superiority to consumers and customers,' Pedro Navio, North America President at Kraft Heinz, said in a statement. 'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio." Kennedy praised the move on a June 17 post to X, formerly Twitter, saying this "voluntary step" will phase out "harmful dyes" in brands like Kool-Aid, Jell-O and Crystal Light. General Mills also announced plans Tuesday to remove "certified colors" from all of its products by the end of 2027, likewise saying that about 85% of its U.S. products are already made without the dyes. It also said that "nearly all" of its school offerings are already free of artificial coloring "Across the long arc of our history, General Mills has moved quickly to meet evolving consumer needs, and reformulating our product portfolio to remove certified colors is yet another example," CEO Jeff Harmening said in a statement on June 17. Are food dyes getting banned in the US?: What know to about 8 dyes being phased out Is the US banning artificial food dyes? The FDA announced on April 22 that it will "phase out all petroleum-based synthetic dyes from the nation's food supply" by the end of 2026. The dyes have previously been allowed under FDA regulations and oversight. The targeted additives include Red Dye 40, Yellow Dye 5, Yellow Dye 6, Blue Dye 1, Blue Dye 2, Green Dye 3, Citrus Red 2 and Orange B. No formal agreement or legislation was passed officially banning the substances. Instead, HHS and the FDA have a "mutual understanding" with the food industry that the dyes will be progressively removed, Kennedy said at the time. During an April 22 press conference, FDA Commissioner Marty Makary said the agency intends to revoke the approval of some dyes for use and work with industry leaders to substitute petrochemical dyes with "natural" ones. A press statement released by the FDA also said it plans to establish a "national standard and timeline for the transition from petrochemical-based dyes to natural alternatives." The FDA will authorize four new natural color additives and expedite the approval of more, according to its statement. The agency will also partner with the National Institutes of Health to research the effect food additives have on children's health and development. Other companies promise to eliminate artificial dyes Several major food and beverage companies have recently announced their plans to remove ingredients in the wake of the April HHS announcement. At an April 24 earnings call, PepsiCo CEO Ramon Laguarta said the company's transition away from artificial colors was underway, with more than 60 percent of its business already in compliance. Popular snack brands under its portfolio like Lays, Doritos and Tostitos, will stop using artificial colors by the end of the year under the directive. Tyson Foods made a similar promise in May, telling Reuters it was "proactively reformulating" products to eliminate the use of petroleum-based synthetic dyes by the end of the month. Mars, Inc., the producer of Skittles, also announced in late May that it would be removing titanium dioxide from the colorful candy. This article originally appeared on USA TODAY: Kraft Heinz, General Mills to remove artificial dyes by end of 2027 Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
Shares of Capricor Therapeutics CAPR tanked 33% on Friday after it announced that the FDA issued a complete response letter ('CRL') to the biologics license application ('BLA') seeking approval for cell therapy deramiocel, to treat cardiomyopathy associated with Duchenne muscular dystrophy ('DMD'). DMD is a serious genetic disorder showing progressive weakness and chronic inflammation of the skeletal, heart and respiratory muscles with mortality at a median age of approximately 30 years. Per the CRL, the FDA informed the company that it had concluded review of the BLA but could not approve the application in the current form. The regulatory body specifically noted that the application failed to meet the statutory requirement for substantial evidence of effectiveness and highlighted the need for additional clinical data. The CRL also highlighted certain unresolved issues within the Chemistry, Manufacturing and Controls ('CMC') section of the application. Management believes that most of these concerns have already been addressed in its prior communications with the FDA. However, the FDA did not review these materials, as they were submitted too close to the issuance of the CRL. Year to date, shares of Capricor have plunged 44.7% compared with the industry's decline of 0.9%. Image Source: Zacks Investment Research CRL to CAPR's BLA Comes as a Major Surprise The investor community seemed surprised by the CRL, especially after the FDA accepted and granted a priority review to the BLA for deramiocel in March. A decision was due on Aug. 31, 2025. More so, the FDA also did not identify any review issues with the BLA. In a regulatory update provided last month, the company also confirmed that the FDA indicated an Advisory Committee meeting would not be required for the application. The BLA was based on data from its phase II HOPE-2 and an open-label extension study compared with natural history data. A potential approval could have made deramiocel the first therapy to treat DMD cardiomyopathy. However, the latest CRL is likely to delay the approval for deramiocel, which could have given Capricor its first approved product. The company plans to hold further discussions with the FDA to determine the next steps of development for deramiocel. Capricor Therapeutics, Inc. Price Capricor Therapeutics, Inc. price | Capricor Therapeutics, Inc. Quote CAPR's Zacks Rank & Stocks to Consider Capricor currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the biotech sector are Arvinas ARVN, Alkermes ALKS and BioXcel Therapeutics BTAI, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, Arvinas' 2025 loss per share estimates have improved from $1.60 to $1.51. Loss per share estimates for 2026 have narrowed from $3.28 to $2.98 during the same period. ARVN stock has plunged 59.3% year to date. Arvinas' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 82.09%. In the past 60 days, estimates for Alkermes' earnings per share have increased from $1.74 to $1.79 for 2025. During the same time, earnings per share estimates for 2026 have risen from $1.79 to $1.91. Year to date, shares of ALKS have gained 5.3%. Alkermes' earnings beat estimates in one of the trailing four quarters, while missing the same on the remaining three occasions, the negative average surprise being 8.24%. In the past 60 days, BioXcel Therapeutics' 2025 loss per share estimates have improved from $16.44 to $8.60. Loss per share estimates for 2026 have narrowed from $23.76 to $7.02 during the same period. BTAI stock has declined 67.1% year to date. BioXcel Therapeutics' earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 42.84%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report Capricor Therapeutics, Inc. (CAPR) : Free Stock Analysis Report BioXcel Therapeutics, Inc. (BTAI) : Free Stock Analysis Report Arvinas, Inc. (ARVN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
